Insider Selling: Amicus Therapeutics, Inc. (NASDAQ:FOLD) COO Sells 10,514 Shares of Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) COO Bradley L. Campbell sold 10,514 shares of the stock in a transaction dated Monday, June 7th. The stock was sold at an average price of $10.01, for a total transaction of $105,245.14. Following the transaction, the chief operating officer now owns 436,397 shares of the company’s stock, valued at $4,368,333.97. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Bradley L. Campbell also recently made the following trade(s):

  • On Monday, May 3rd, Bradley L. Campbell sold 10,514 shares of Amicus Therapeutics stock. The stock was sold at an average price of $10.27, for a total transaction of $107,978.78.

Shares of FOLD opened at $10.71 on Friday. Amicus Therapeutics, Inc. has a 12 month low of $8.68 and a 12 month high of $25.39. The stock’s 50 day simple moving average is $9.63. The company has a market capitalization of $2.85 billion, a PE ratio of -11.04 and a beta of 1.15. The company has a debt-to-equity ratio of 1.55, a current ratio of 5.05 and a quick ratio of 4.86.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Sunday, May 9th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.01). The business had revenue of $66.40 million for the quarter, compared to the consensus estimate of $71.76 million. Amicus Therapeutics had a negative return on equity of 80.85% and a negative net margin of 95.05%. As a group, sell-side analysts forecast that Amicus Therapeutics, Inc. will post -0.85 EPS for the current year.

A number of large investors have recently made changes to their positions in the stock. Tygh Capital Management Inc. increased its stake in Amicus Therapeutics by 0.4% in the fourth quarter. Tygh Capital Management Inc. now owns 130,158 shares of the biopharmaceutical company’s stock valued at $3,005,000 after acquiring an additional 577 shares during the last quarter. Aperio Group LLC increased its stake in Amicus Therapeutics by 1.2% in the fourth quarter. Aperio Group LLC now owns 49,436 shares of the biopharmaceutical company’s stock valued at $1,141,000 after acquiring an additional 585 shares during the last quarter. Pacer Advisors Inc. increased its stake in Amicus Therapeutics by 20.9% in the first quarter. Pacer Advisors Inc. now owns 7,238 shares of the biopharmaceutical company’s stock valued at $72,000 after acquiring an additional 1,252 shares during the last quarter. Profund Advisors LLC increased its stake in Amicus Therapeutics by 6.2% in the fourth quarter. Profund Advisors LLC now owns 23,509 shares of the biopharmaceutical company’s stock valued at $543,000 after acquiring an additional 1,371 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in Amicus Therapeutics by 15.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 10,330 shares of the biopharmaceutical company’s stock valued at $239,000 after buying an additional 1,400 shares in the last quarter.

A number of equities analysts have recently commented on FOLD shares. Stifel Nicolaus assumed coverage on shares of Amicus Therapeutics in a research note on Monday, March 8th. They set a “hold” rating and a $13.00 price objective for the company. Robert W. Baird reiterated a “buy” rating on shares of Amicus Therapeutics in a research note on Wednesday, March 3rd. Cantor Fitzgerald upgraded shares of Amicus Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Monday, April 19th. Citigroup cut their target price on shares of Amicus Therapeutics from $27.00 to $16.00 in a research note on Friday, February 12th. Finally, Needham & Company LLC assumed coverage on shares of Amicus Therapeutics in a research note on Thursday, May 27th. They issued a “hold” rating for the company. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $20.00.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates.

Recommended Story: Resistance Level

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.